144: Filer Information
| Filer CIK | 0001750094 |
| Filer CCC | XXXXXXXX |
| Is this a LIVE or TEST Filing? |  LIVE
 TEST
|
Submission Contact Information | |
| Name | |
| Phone | |
| E-Mail Address |
| Form 144 Filer Information |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144
NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 | |
FORM 144 |
144: Issuer Information
| Name of Issuer | Roivant Sciences Ltd. |
| SEC File Number | 001-40782 |
| Address of Issuer | 7th Floor 50 Broadway London UNITED KINGDOM SW1H 0DB |
| Phone | 44 207 400 3347 |
| Name of Person for Whose Account the Securities are To Be Sold | Gline Matthew |
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account
the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given
as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales
for the account of the person filing this notice.
| |
| Relationship to Issuer | Director |
| Relationship to Issuer | CEO |
144: Securities Information
| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange |
|---|---|---|---|---|---|---|
| Common shares, $0.0000000341740141 par value per share ("Common Shares") | E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005 | 19792 | 174169.6 | 803921356 | 11/21/2023 | Nasdaq |
Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment
of all or any part of the purchase price or other consideration therefor:
144: Securities To Be Sold
| Title of the Class | Date you Acquired | Nature of Acquisition Transaction | Name of Person from Whom Acquired | Is this a Gift? | Date Donor Acquired | Amount of Securities Acquired | Date of Payment | Nature of Payment * |
|---|---|---|---|---|---|---|---|---|
| Common Shares | 11/20/2023 | Restricted Stock Units granted under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan | Roivant Sciences Ltd. |  | 19792 | 11/20/2023 | N/A |
* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note
thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made
in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.
Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.
144: Securities Sold During The Past 3 Months
| Name and Address of Seller | Title of Securities Sold | Date of Sale | Amount of Securities Sold | Gross Proceeds |
|---|---|---|---|---|
| Matthew Gline c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X1 SW1H 0DB | Common Shares | 08/22/2023 | 11015 | 119292.45 |
| Matthew Gline c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X1 SW1H 0DB | Common Shares | 08/28/2023 | 6784 | 76320 |
| Matthew Gline c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X1 SW1H 0DB | Common Shares | 09/22/2023 | 11227 | 114403.13 |
| Matthew Gline c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X1 SW1H 0DB | Common Shares | 09/28/2023 | 10243 | 129778.81 |
| Matthew Gline c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X1 SW1H 0DB | Common Shares | 10/24/2023 | 12489 | 112276.11 |
144: Remarks and Signature
| Remarks | The securities included in Table I represent a maximum number of shares that may be sold to cover the reporting person's tax obligations when restricted stock units belonging to the reporting person are settled. The securities included in Table II represent shares sold to cover the reporting person's tax obligations when restricted stock units or capped value appreciation rights belonging to the reporting person were settled. Table II does not include shares that were "net settled" by the Issuer in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units or capped value appreciation rights previously granted to the reporting person. The securities reported in Tables I and II do not represent discretionary trades by the reporting person, and will be sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations. |
| Date of Notice | 11/21/2023 |
| Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 | 02/22/2022 |
ATTENTION: | |
| The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. | |
| Signature | /s/ Matthew Gline |
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001) | |